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Abstract
Background: Ceramide accumulation is considered a contributing factor to neuronal dysfunction and damage.
However, the underlying mechanisms that occur following ischemic insult are still unclear.
Methods: In the present study, we established cerebral ischemia models using four-vessel occlusion and oxygen-
glucose deprivation methods. The hippocampus neural cells were subjected to immunohistochemistry and
immunofluorescence staining for ceramide and neutral sphingomyelinase 2 (nSMase2) levels; immunoprecipitation
and immunoblot analysis for nSMase2, receptor for activated C kinase 1 (RACK1), embryonic ectoderm
development (EED), p38 mitogen-activated protein kinase (p38MAPK) and phosphorylated p38MAPK expression;
SMase assay for nSMase and acid sphingomyelinase (aSMase) activity; real-time reverse transcription polymerase
chain reaction for cytokine expression; and Nissl, microtubule-associated protein 2 and terminal deoxynucleotidyl
transferase–mediated deoxyuridine triphosphate nick-end labeling staining.
Results: We found considerable production of ceramide in astrocytes, but not in neurons, during early cerebral
ischemia. This was accompanied by the induction of nSMase (but not aSMase) activity in the rat hippocampi. The
inhibition of nSMase2 activity effectively reduced ceramide accumulation in astrocytes and alleviated neuronal
damage to some extent. Meanwhile, the expression levels of proinflammatory cytokines, including tumor necrosis
factor α (TNF-α), interleukin 1β (IL-1β) and IL-6, were found to be upregulated, which may have played an import
role in neuronal damage mediated by the nSMase2/ceramide pathway. Although enhanced binding of nSMase2
with RACK1 and EED were also observed after cerebral ischemia, nSMase2 activity was not blocked by the TNF-α
receptor inhibitor through RACK1/EED signaling. p38MAPK, but not protein kinase Cζ or protein phosphatase 2B,
was able to induce nSMase2 activation after ischemia. p38MAPK can be induced by A2B adenosine receptor
(A2BAR) activity.
Conclusions: These results indicate that the inhibition of ceramide production in astrocytes by targeting
A2BAR/p38MAPK/nSMase2 signaling may represent a viable approach for attenuating inflammatory responses
and neuronal damage after cerebral ischemia.
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Background
Ischemic stroke, usually induced by a temporary or
permanent reduction of local cerebral blood flow, is the
leading cause of death and disability in humans [1-5].
Among the several molecular mechanisms that contribute
to ischemia-induced brain damage, inflammation plays a
crucial role. It not only is involved in the pathophysiology
of cerebral ischemia but also is recognized as being a risk
factor for ischemic insult. Recent studies suggest that
astrocytes are involve vitally in neuroinflammation through
the release of cytotoxic agents in response to ischemia
stimuli, which can contribute to blood–brain barrier
disruption and delayed neuronal damage [6-8]. However,
the mechanisms underlying inflammation in astrocytes
after ischemia remain unclear.
Ceramide, a liposoluble messenger, has been identified
as an important signaling molecule in cell growth arrest,
differentiation, senescence, apoptosis and inflammation
[9-13]. After ceramide generation, a number of signaling
molecules, including c-Jun N-terminal kinase (JNK), protein
kinase Cζ (PKCζ), stress-activated protein kinase, kinase
suppressor of Ras, protein phosphatase 1 (PP1) and PP2A,
can be activated to regulate the intracellular signaling path-
way and induce a stress reaction in the target cells [14-17].
Our studies found that in the early stage of acute brain
ischemic injury, specific accumulation of ceramide was
notable in hippocampus astrocytes but not in neurons,
which might be associated with neuroinflammation in the
postischemic brain tissue [18,19].
In many cases, sphingomyelin (SM) hydrolysis by
sphingomyelinase (SMase) appears to be a major,
rapid source of ceramide production in response to
various conditions, such as hypoxia, oxidative stress
and ultraviolet irradiation [20-22]. SMase can be di-
vided into several subtypes according to different pH
optima and subcellular localizations, such as neutral
sphingomyelinase (nSMase) localized in the plasma
membrane and acid sphingomyelinase (aSMase) localized
in endosomal-lysosomal compartments [23,24]. Among
the subtypes of nSMase, nSMase2 is considered to be an
important candidate for ceramide production in the neural
membrane [25,26].
nSMase2 activation is closely associated with its WD re-
peat domain and the phosphorylation of special sites [25].
For example, the activity of nSMase2 can be stimulated by
tumor necrosis factor α (TNF-α) through the formation of
a WD-binding complex (TNF-R1-FAN-RACK1-nSMase2)
[27,28]. In addition, it has recently been reported that
embryonic ectoderm development (EED) may be the last
missing link between receptor for activated C kinase 1
(RACK1) and nSMase2 [29]. Moreover, nSMase2 is also
recognized as a phosphoprotein with five highly conserved
serine residues (S173, S208, S289, S292 and S299), and its
activity can be regulated by kinases and phosphatases in
response to certain stresses [30,31]. p38, PKCδ and PP2B
have been recognized as being upstream of nSMase2, which
can regulate its activity through serine phosphorylation and
dephosphorylation [32-34]. Moreover, p38 pathways have
been found to be involved in the A2B adenosine receptor
(A2BAR)-mediated inflammatory response [35,36].
The four-vessel occlusion (4-VO) procedure is widely
used to induce forebrain ischemia and cause delayed
neuronal death in the rat hippocampus, especially in its
CA1 region, similarly to the clinical rationale in ischemic
stroke. During cerebral ischemia, ceramide production is
thought to be closely associated with neuron damage in
the hippocampal region [8,9]. Astrocytes are now recog-
nized as innate immunocytes which possess the potential
to release various kinds of inflammatory mediators [37,38].
Therefore, we propose that cerebral ischemia can stimulate
nSMase2-induced SM hydrolysis and ceramide production
in astrocytes, which is followed by the production and re-
lease of inflammatory mediators from activated astrocytes.
These inflammatory mediators in turn act on neurons
and aggravate secondary damage of neurons in the central
nervous system.
Methods
Animal model of ischemia
All animal experiments were performed in accordance with
the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health and approved by the
Institutional Animal Care and Use Committee of Nanjing
Medical University, China. Adult male Sprague–Dawley
rats (purchased from the Experimental Animal Center of
Nanjing Medical University) weighing 220 to 250 g were
used in the study.
The method of inducing transient global ischemia was
performed as described previously [39,40]. All animals
(except the sham controls) underwent 4-VO. Briefly,
the animals were anesthetized with 10% chloral hydrate
(350 mg/kg intraperitoneal injection), then the vertebral
arteries were occluded by electrocautery. On the following
day, 4-VO ischemia was induced for 10 min by occluding
the bilateral common carotid arteries with aneurysm clips.
Animals that lost their righting reflex within 30 s and whose
pupils were dilated and unresponsive to light were used for
the subsequent experiments. After 10 min of ischemia, the
clips were removed for reperfusion. The animals in the
sham group underwent the same surgical procedure;
however, the carotid arteries were only exposed and
not occluded. During the experiment, the rats’ body
temperature was maintained at around 36.5°C.
Infusion and administration of drugs or small
interfering RNA
The drugs or their vehicles were injected into the lateral
ventricles (0.8 mm posterior and 1.5 mm lateral to the
Gu et al. Journal of Neuroinflammation 2013, 10:109 Page 2 of 16
http://www.jneuroinflammation.com/content/10/1/109
bregma, 3.5 mm deep) using a microinjector 30 min before
the induction of ischemia, as described in previous reports
[39,40]. The compounds used are listed in Table 1.
For the administration of small interfering RNA
(siRNA), 5 μl of control siRNA (a scrambled siRNA) or
nSMase2 siRNA (20 μM; RiboBio Co, Guangzhou, China)
were diluted with the same volume of transfection reagent
(Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
injection was repeated four times, every 12 h, starting
2 days before ischemia induction, as described previously
[40]. After injection, the needle was kept in place for 5 min.
Isolation of primary rat neurons and astrocytes
Under sterile conditions, the hippocampi were dissected
from neonatal rats on postnatal day 1 and then dissociated
by trituration and trypsinization (0.25% trypsin in
Dulbecco’s modified Eagle’s medium (DMEM) at 37°C for
15 min). Digestion was terminated with 10% fetal bovine
serum (FBS) (Gibco/Life Technologies, Grand Island, NY,
USA), then the tissues were filtered through 200-μm mesh.
The samples were centrifuged at 5,000 g for 5 min. Primary
rat neurons were cultured in neurobasal medium with 2%
B27 supplement and 1% antibiotic-antimycotic mixture
(Gibco/Life Technologies) at 37°C in a 5% CO2 atmosphere.
At the same time, the primary rat astrocytes were cultured
in DMEM with 10% FBS at 37°C in a 5% CO2 atmosphere.
Oxygen-glucose deprivation model
Before exposure to oxygen-glucose deprivation (OGD) con-
ditions, the culture medium was changed to glucose-free
DMEM without serum as described in previous reports
[41,42]. The astrocytes were exposed to 0.1% O2, 5% CO2
and 94.4% nitrogen for 3 h or 6 h at 37°C, then they were
returned to the culture medium with glucose and serum
supplement for 30 min at 37°C in a 5% CO2 atmosphere.
Immunohistochemistry and immunofluorescence
Rats were perfused with 0.9% saline and 4% paraformal-
dehyde. The brains were frozen, sectioned (20 μm)
and blocked with 3% bovine serum albumin (BSA)
(0.1% Tween 20) for 30 min at 4°C. The immunohis-
tochemistry samples were incubated for 10 min with
1% H2O2 and then blocked. The sections were incu-
bated with primary antibodies, including nSMase2
(1:200; Santa Cruz Biotechnology), ceramide (1:200;
Sigma-Aldrich, St Louis, MO, USA), glial fibrillary acidic
protein (1:500; EMD Millipore, Billerica, MA, USA) and
NeuN (1:500; Millipore), for 24 h at 4°C. The slides were
further examined using secondary antibodies labeled
with tetramethylrhodamine isothiocyanate, fluorescein/
rhodamine isothiocyanate or horseradish peroxidase
(HRP). Finally, the immunohistochemistry stained sections
were incubated with 3,3′-diaminobenzidine (DAB) reagent.
Images were captured using a fluorescence microscope
and analyzed using ImageJ software (National Institutes of
Health, Bethesda, MD, USA).
Nissl staining
Sections mounted on poly-L-lysine-coated slides were
dehydrated with ethanol and then treated with xylene
for 5 min. After being washed with double-distilled
water, the sections were incubated with 1% cresyl violet
(Sigma-Aldrich) solution for 5 min at 50°C and then
dehydrated with ethanol. Images were captured using a
visible microscope objective.
Coimmunoprecipitation and immunoblotting
The hippocampi were dissected and harvested in lysis
buffer containing a protease inhibitor cocktail (Sigma-
Aldrich), 50 mM Tris•HCl, 150 mM NaCl, 1% Triton
X-100, 1 mM ethylenediaminetetraacetic acid, 1 mM
phenylmethylsulfonyl fluoride, 1 mM NaF and 1 mM
NaVO4 (pH 7.4). The same amounts of the lysates
were incubated with 40 μg of nSMase2 antibody
(Santa Cruz Biotechnology) overnight at 4°C. The protein
A agarose sphere (Santa Cruz Biotechnology) was added to
the samples and stored at 4°C. After 2 h, the samples were
washed three times with lysis buffer, and the immune com-
plexes were collected. Part of the immunoprecipitation
(IP)-purified nSMase2 was prepared for activity analysis,
Table 1 Signal transduction inhibitors or agonists and their corresponding targetsa
Agent Abbreviation Target Company
GW4869 nSMase2 inhibitor Santa Cruz Biotechnology
Daunorubicin DNR nSMase2 agonist
R-7050 TNF-α receptor antagonist
SB-203580 p38MAPK inhibitor
PP2B inhibitor dithiocarbamate PP2B inhibitor
Imipramine Lim aSMase inhibitor Sigma-Aldrich
MRS-1754 Selective antagonist for A2B adenosine receptors
Rottlerin PKCδ inhibitor Enzo Life Sciences
aaSMase acid sphingomyelinase, nSMase2 neutral sphingomyelinase 2, p38MAPK p38 mitogen-activated kinase, PKCδ protein kinase Cδ, PP2B protein phosphatase
2B, TNF-α tumor necrosis factor α.
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and another part was eluted using Laemmli buffer
with 5% mercaptoethanol, before being boiled for 10 min.
Anti-RACK1 (1:500; Cell Signaling Technology, Danvers,
MA, USA) and anti-EED (1:500; Santa Cruz Biotechnology)
antibodies were used for immunoblotting.
Denatured samples were separated by 10% SDS-PAGE
and then electrotransferred onto a nitrocellulose membrane.
After being blocked for 3 h, membranes were incubated
with primary antibodies, including nSMase2 (1:500; Santa
Cruz Biotechnology), RACK1 (1:500; Cell Signaling
Technology), EED (1:500; Santa Cruz Biotechnology),
p38MAPK (1:500; Santa Cruz Biotechnology), phosphory-
lated p38MAPK (1:1,000; Cell Signaling Technology) and
β-actin (1:1,000; Santa Cruz Biotechnology) overnight at
4°C. The immunocomplex was also left to react with
HRP-conjugated secondary antibodies. Finally, the signals
on membranes were analyzed using the Jieda Image
Analysis System (Jiangsu Jeda Science-Technology Co
Ltd, Nanjing, China).
Acid and neutral sphingomyelinase enzyme activities
SMase activity was analyzed using the Amplex Red
Sphingomyelinase Assay Kit (Invitrogen/Life Technologies,
Carlsbad, CA, USA). Briefly, the total protein (50 μg) was
mixed with enzyme assay buffer (100 μl; pH 7.4) and added
to a 96-well microtiter plate. The working solution, which
contained choline oxidase (0.2 U/ml), alkaline phosphatase
(8 U/ml), HRP (2 U/ml), Amplex Red reagent (0.1 mM)
and SM (0.5 mM), was mixed in each well. The 96-well
plate was incubated for 1 h at 37°C. Exposure to light was
avoided. The Amplex Red reagent reacts to generate the
specific fluorescent product, which was measured using
the fluorescence plate reader at 571-nm excitation and
585-nm emission. The assay mixture for aSMase contained
0.1 mM acetate buffer (pH 5.8). The activity of nSMase2
was assessed using the Amplex Red Sphingomyelinase
Assay Kit as described in previous reports [43]; however, the
sample was the IP-purified enzyme (about 5 μg in 100 μl of
elution buffer), not the total protein.
RNA extraction and quantitative real-time polymerase
chain reaction
Total RNA was isolated from hippocampal tissue using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions. Reverse transcription
was performed using the PrimeScript RT Reagent Kit
(TaKaRa Biotechnology, Dalian, China) according to
the manufacturer’s protocol. The expression levels of
the mRNA were analyzed using the SYBR Premix Ex Taq
real-time quantitative PCR kit (TaKaRa Biotechnology)
according to the manufacturer’s instructions. Real-time
PCR was performed using the Eppendorf MasterCycler
RealPlex Sequence Detection System (Life Technologies,
Grand Island, NY, USA). Data analysis was performed
using the 2-ΔΔCT method.
Astrocyte/neuron Transwell study
Primary rat astrocytes were cultured on permeable
membranes using Millicell cell culture inserts (0.4-mm
pore size; EMD Millipore) in six-well plates for 2 days at
37°C in a 5% CO2 Atmosphere. After 24 h of stimulation
with the nSMase2 agonist daunorubicin (DNR; 0.5 μM),
the inserts were placed onto the wells containing primary
rat neurons. In this Transwell (Corning, Tewksbury, MA,
USA) model, neurons were in the lower chambers facing
each other, and astrocytes were kept independent in the
upper chambers. Following the independent analysis of
neuronal and glial groups, the soluble factors released
from activated astrocytes could act upon the primary rat
neurons in the lower chambers.
Microtubule-associated protein 2 staining
Primary rat neurons in coverslips were fixed for 10 min at
room temperature in 4% paraformaldehyde. After fixation,
neurons were washed three times, treated with phosphate-
buffered saline (PBS) plus 1% Tween 20 for 10 min at room
temperature and blocked using 4% BSA. Staining for
microtubule-associated protein 2 (MAP2) was performed
using a rabbit anti-MAP2 antibody (1:200; Bioss, Woburn,
MA, USA) for immunofluorescence as described above,
then treated with 4′,6-diamidino-2-phenylindole stain
(Invitrogen/Life Technologies).
TUNEL assay
The terminal deoxynucleotidyl transferase–mediated
deoxyuridine triphosphate nick-end labeling (TUNEL) assay
was performed using the In Situ Cell Death Detection Kit
(KGA702; KeyGEN Biotech, Nanjing, China) according to
the manufacturer’s instructions. Briefly, after being perme-
abilized with 0.1% PBS-Triton X-100 for 5 min and blocked
with 3% H2O2 for 10 min, the slides were incubated with
TUNEL reaction mixture, including equilibration buffer,
biotin-labeled deoxyuridine triphosphate (Biotin-11-dUTP)
and terminal deoxynucleotidyl transferase enzyme, for 1 h
at 37°C. The neurons were treated with streptavidin-HRP
for 30 min at room temperature and incubated with
DAB reagent.
Data analysis
All data are expressed as the mean ± SD values from
at least four animals. Statistical analysis was conducted
using one-way analysis of variance followed by the
Newman–Keuls test. Comparisons between the two groups
were performed using Student’s t-test. P values <0.05 were
considered significant.
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Results
Ceramide induced by cerebral ischemia accumulates in
hippocampal astrocytes and is related to sphingomyelin
hydrolysis
Studies have shown that some harmful factors in neuro-
degenerative diseases (such as Alzheimer disease) can
stimulate nSMase to produce ceramide, inducing
astrocyte activation, the release of neurotoxic molecules
and neuronal damage [9,10,14,44]. To investigate whether
the nSMase/ceramide pathway is involved in cerebral
ischemia-reperfusion (I/R) regulation, we first established a
forebrain ischemia rat model (4-VO). Immunohistochemis-
try and immunofluorescence double-staining were carried
out to detect the morphological localization of ceramide in
rat hippocampi.
After 10 min of ischemia followed by 30 min of reperfu-
sion, a considerable level of ceramide was found in CA1,
CA2 and CA3/dentate gyrus (DG) hippocampal areas
(Figure 1A), primarily in astrocytes but not in neurons
(Figures 1B and C). As reported previously [23-26,44],
SM hydrolysis can be an important means of rapidly
generating ceramide. To further explore the molecular
mechanism underlying ceramide accumulation induced
by cerebral ischemia, inhibitor GW4869 and siRNA of
nSMase2, and aSMase inhibitor imipramine (Lim; 10 μM),
respectively, were injected into the cerebral ventricle prior
to ischemia. The results indicated that ceramide levels in
the hippocampus were decreased after treatment with
GW4869 and nSMase2 siRNA (0.42-fold vs. vehicle or
0.47-fold vs. control siRNA; P < 0.05) (Figures 1D and F),
but that there was no obvious change after Lim treat-
ment (Figure 1E). Furthermore, the specificity of the
staining was confirmed by replacement of the primary
antibody with isotype-matched nonimmune immuno-
globulin G or serum. Taken together, the results sug-
gest that ischemia-induced ceramide accumulation
was located specifically in rat hippocampal astrocytes.
This might derive from SM hydrolysis by nSMase,
especially nSMase2, but it has no connection with
aSMase.
Figure 1 Ceramide localization in rat hippocampus postischemia and effects of neutral sphingomyelinase 2 and acid
sphingomyelinase inhibitors on ceramide. (A) Ceramide levels in rat CA1, CA2 and CA3/dentate gyrus hippocampal areas were detected by
immunohistochemistry in the ischemia-reperfusion (I/R) 30-min and sham control groups. (B) Double-staining of ceramide and glial fibrillary
acidic protein in rat CA1 hippocampal area in the I/R 30-min group was detected using immunofluorescence. (C) Double-staining of ceramide
and NeuN in rat CA1 hippocampal area in the I/R 30-min group was detected using immunofluorescence. Different drugs or small interfering
RNA (siRNA) were injected into the lateral ventricle prior to the 10-min ischemia and 30-min reperfusion procedure. Drugs included GW4869 or
its vehicle (D), imipramine (Lim) or its vehicle (E) and neutral sphingomyelinase 2 siRNA or control siRNA (F). Immunohistochemistry was
subsequently carried out to detect ceramide expression levels (n = 4).
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Neutral sphingomyelinase 2 activity in astrocytes is
quickly upregulated after cerebral ischemia
To confirm the speculation that nSMase (primarily
nSMase2) might participate in the production of cer-
amide following I/R, a SM enzyme activity assay kit
was used to examine the activities of nSMase, aSMase and
nSMase2. In this study, the hippocampal tissues were
extracted following different durations of cerebral I/R (0.5,
1, 6, 12 and 24 h).
As the time curve results show (Figure 2A), nSMase
activity increased (compared with the control), and it
reached 373.1% at I/R 30 min (P < 0.05), 317.6% at I/R 1 h
(P < 0.05) and 246.2% at I/R 6 h (P < 0.05), but there were
no differences for aSMase activity (P > 0.05). Moreover,
GW4869 prompted considerable activity of nSMase
(P < 0.05), but not of aSMase (Figure 2B), suggesting
that nSMase2 might be the most important component of
nSMase in the neural cells [25,26].
nSMase2 activity following cerebral ischemia was sub-
sequently examined. nSMase2 protein was immuno-
precipitated with a special antibody and analyzed using a
SMase assay kit. nSMase2 activity at I/R 30 min, I/R 1 h
and I/R 6 h all increased (P < 0.05), particularly at I/R
30 min. nSMase2 protein levels for each group were
almost parallel, indicating that the difference was due to its
own activity (Figure 2C). The protein was predominantly
expressed in astrocytes in the CA1, CA2 and CA3/DG
hippocampal areas (Figure 2D).
Taken together, the findings suggest that it is nSMase
(mainly nSMase 2), not aSMase, that was initiated at the
early stage of cerebral I/R and which played a significant
role in the generation of ceramide in rat hippocampal
astrocytes.
Early initiation of neutral sphingomyelinase 2 induces
neuronal damage associated with cerebral
ischemia-reperfusion
Ceramide accumulation has been suggested to be an
important factor in the development of ischemia lesions
[9,10]. To determine the involvement of ceramide in
neuronal injury associated with cerebral I/R, we utilized
Nissl staining in the present study. Brain tissue was
extracted at different times (3 d and 7 d) following cere-
bral I/R. Compared with the control group, the number of
Nissl bodies in the neurons of rat hippocampi in the CA1
area was reduced at I/R 3 d. This effect was even greater
at I/R 7 d (Figure 3A). However, neuronal damage was
somewhat alleviated with GW4869 or nSMase2 siRNA
treatment, but Lim had no effect (Figures 3B, C and E).
This indicates the participation of nSMase2, but not
aSMase, in neuronal damage induced by cerebral I/R.
To explore this finding further, the nSMase2 agonist
DNR (0.5 μM) was used [45], which revealed that the
number of Nissl bodies was remarkably reduced by
DNR (Figure 3D). In addition, the TUNEL assay results
(similar to those revealed by Nissl staining) also suggested
that nSMase2 had some involvement in the apoptosis of
neurons post-ischemia (Figure 3F). Overall, it is suggested
that the nSMase2/ceramide pathway in astrocytes was
linked to the neuronal damage after cerebral ischemia
in vivo.
TNF-αR/RACK1/EED pathway partly mediates early
initiation of neutral sphingomyelinase 2 during ischemia
Given that the internal cell TNF-α receptor-FAN-RACK1-
EED-nSMase2 complex mediated by TNF-α stimulation
could increase nSMase2 activity [27-29], coimmuno-
precipitation technology was applied to detect the under-
lying mechanism associated with the different durations of
I/R (0.5, 1, 6 and 24 h), and control experiments without
the primary antibodies were performed to prove the specifi-
city of the binding in the preliminary study. As the data
in Figures 4A and B show, the combination of nSMase2/
RACK1 and that of nSMase2/EED were augmented at I/R
30 min (P < 0.05), peaked at I/R 1 h (P < 0.05) and then
gradually declined after I/R 24 h. Following treatment with
the TNF-α receptor (TNF-αR) inhibitor R-7050 (10 μM),
the combination of nSMase2/RACK1 or nSMase2/EED
declined significantly in comparison to the solvent group
(P < 0.05) (Figure 4C). Incidentally, nSMase2 activity was
found to be partially reduced (P < 0.05) but remained
significantly higher than that of the control group. There
was no obvious variation in aSMase activity (P > 0.05)
(Figure 4D). These results indicate that, in addition to
the TNF-αR/RACK1/EED pathway, there might be other
signals involved in ischemia-induced early initiation of
nSMase2 in rat hippocampi.
nSMase2 phosphorylation induced by p38MAPK is an
important mechanism underlying nSMase2/ceramide
pathway signaling during cerebral ischemia
Phosphorylation has been regarded as an important mech-
anism for nSMase2 activity. For example, p38MAPK, PKCζ
and PP2B may regulate nSMase2 activity through
phosphorylation [32-34]. To explore whether this under-
lying mechanism plays a key role in nSMase2 activity after
cerebral ischemia, the p38MAPK inhibitor SB-203580,
the PKCζ inhibitor rottlerin and the PP2B inhibitor
were injected into the lateral ventricle, respectively.
According to the data shown in Figures 5A, B and C,
only SB-203580 could significantly inhibit nSMase
activity in a dose-dependent manner (P < 0.05). To
further investigate the effect of p38MAPK, PKCδ and
PP2B on nSMase2 activity, the specificity of detection was
examined after each inhibitor treatment (Figure 5D).
SB-203580 was found to inhibit nSMase2 activity (P < 0.05),
PP2B inhibitor enhanced its activity (P < 0.05) and rottlerin
had little influence (P > 0.05). In addition, the nSMase2
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protein content of each group appeared to be similar,
implying that the difference was due to its own activity.
nSMase2 phosphorylation induced by p38MAPK therefore
appeared to play an important role in the rise of activity
that occurred after cerebral I/R, whereas PP2B was linked
to nSMase2 dephosphorylation and inactivation.
Figure 2 Cerebral ischemia induced rapid activation of neutral sphingomyelinase and neutral sphingomyelinase 2 in rat hippocampal
astrocytes. (A) After postischemic reperfusion of different durations (30 min, 1 h, 6 h, 12 h and 24 h), neutral sphingomyelinase (nMase) or acid
sphingomyelinase (aSMase) activity in the rat hippocampus was detected. (B) GW4869 and its solvent were separately injected into the lateral
ventricle prior to the 30-min post-ischemia-reperfusion (post-I/R) procedure, and activity levels of nSMase and aSMase in the rat hippocampi were
then measured. (C) After different durations of post-I/R (30 min, 1 h and 6 h), activity and protein expression levels of nSMase2 in the rat
hippocampus were measured. (D) Examination of nSMase2 expression levels in rat CA1, CA2 and CA3/dentate gyrus hippocampal areas and
double-staining of nSMase2 and glial fibrillary acidic protein in the CA1 area of normal groups were carried out by immunohistochemistry and
immunofluorescence, respectively. Data are representative of the means ± SEM of four separate experiments (n = 4). *P < 0.05 vs. sham control.
#P < 0.05 vs. ischemia solvent control.
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A2B adenosine receptor regulates the initiation of
nSMase2/ceramide pathway signaling stimulated by
p38MAPK during cerebral ischemia
p38MAPK is an important member of the MAPK family
which is involved in the regulation of cell differentiation,
apoptosis and inflammation [46,47]. p38MAPK phos-
phorylation induced by A2BAR in gliomas can participate
in the regulation of inflammation [35,36]. To clarify the
possible involvement of A2BAR in p38MAPK phosphoryl-
ation, nSMase2 activation and ceramide production, the
A2BAR inhibitor MRS-1754 (10 μg/μl) was administered
following I/R. First, Western blot analysis showed that
p38MAPK phosphorylation levels significantly increased
after 30 min of I/R (P < 0.05) (Figure 6A) and subsequently
decreased after 1 h and 6 h, but levels remained higher than
those in the control group (P < 0.05). Second, MRS-1754
reversed the elevation of p38MAPK phosphorylation at
30 min (P < 0.05) (Figure 6B). In addition, MRS-1754
significantly inhibited nSMase2 activity (P < 0.05)
(Figure 6C) but had no influence on aSMase activity
(P > 0.05, data not shown). The immunohistochemical
results revealed that ceramide levels were reduced in
the rat hippocampi with the inhibition of A2BAR by
MRS-1754 (Figure 6D). Taken together, the results
suggest that A2BAR participated in the increment of
nSMase2 activity induced by p38MAPK phosphorylation
and the accumulation of ceramide during cerebral I/R.
Neutral sphingomyelinase 2 involved in inflammation
factor production in astrocytes following cerebral
ischemia
Oxidative stress and inflammation are important patho-
logical factors in cerebral ischemic lesions [3,4]. Real-time
PCR was used to detect the mRNA levels of inflammatory
cytokines such as IL-1β, IL-6 and TNF-α associated with
nSMase2 activation. After the nSMase2 agonist DNR was
injected into the lateral ventricle, IL-6 mRNA levels started
to rise at 1 h, peaked at 12 h and began to decline at 24 h
(P < 0.05) (Figure 7A). The mRNA levels of IL-6 and
TNF-α significantly increased at 12 h and did not decline
until 24 h after treatment (P < 0.05) (Figure 7A). These
data indicate that the activation of nSMase2 could drive
the generation and release of inflammatory cytokines. To
explore this hypothesis further, the nSMase2 inhibitor
GW4869 and the nuclear factor κB (NF-κB) inhibitor pyr-
rolidine dithiocarbamate (PDTC) were injected into the rat
Figure 3 Effect of neutral sphingomyelinase 2 on ischemic neuronal damage associated with cerebral ischemia. Neuronal damage in the
rat CA1 hippocampal area was detected in the different groups that received different treatments using Nissl staining. (A) Postischemic
reperfusion of different durations (3 d and 7 d) and control groups. (B) and (C) Injection with GW4869, imipramine (Lim) and their solvent into
the lateral ventricle, respectively, followed by 7-d postischemic reperfusion. (D) Normal group with daunorubicin (DNR) stimulus for 24 h. (E)
Effect of neutral sphingomyelinase 2 (nSMase2) small interfering RNA (siRNA) and control siRNA on the rat CA1 hippocampal neurons
postischemia. (F) Terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling assays showing apoptosis in the
rat CA1 hippocampal neurons postischemia and effect of nSMase2 siRNA on them (n = 4).
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hippocampus prior to ischemia, respectively. The real-time
PCR findings (shown in Figures 7B and 7C) suggest that
the inhibition of both nSMase2 and NF-κB activity could
significantly reduce the mRNA levels of IL-1β, IL-6 and
TNF-α (P < 0.05). Taken together, the activation of
nSMase2 in astrocytes is suggested to have induced the
production and release of IL-1β, IL-6 and TNF-α through
NF-κB activity, thereby mediating the hippocampal
neuronal damage that occurred during cerebral I/R.
Ceramide accumulation in astrocytes is involved in
damage of peripheral neurons following cerebral
ischemia
To confirm the speculation that cerebral ischemia can
induce peripheral neuronal damage through the nSMase2/
ceramide pathway in astrocytes, an in vitro OGD model of
rat primary astrocytes and a coculture model of primary
astrocytes/primary neurons were established. All results in
this study reflect activity at the cellular level. The findings
Figure 4 Effect of the TNF-αR/RACK1 pathway on early activation of ischemia-induced neutral sphingomyelinase 2. (A) and (B) The
binding effects of neutral sphingomyelinase 2 (nSMase2) with receptor for activated C kinase 1 (RACK1) and embryonic ectoderm development
(EED) were detected using coimmunoprecipitation after postischemic reperfusion of different durations (0.5 h, 1 h, 6 h and 24 h). (C) and (D) The
binding effect of nSMase2 with RACK1 and EED was detected using coimmunoprecipitation after R-7050 or solvent was injected into the lateral
ventricle with 30 min postischemic reperfusion. (E) Samples were extracted for the R-7050 drug group, the ischemic group, the solvent group
and the sham group to detect nSMase2 activity and protein expression levels. Data are presented as means ± SEM of four separate experiments
(n = 4). *P < 0.05 vs. sham control. #P < 0.05 vs. ischemia solvent control.
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Figure 5 Effect of p38 mitogen-activated protein kinase, protein phosphatase 2B or protein kinase Cδ inhibitors on initiation of
neutral sphingomyelinase 2 following ischemia. Some inhibitors and their solvents were separately injected into the lateral ventricle, followed
by 30-min postischemic reperfusion. Effects of p38 mitogen-activated protein kinase (p38MAPK) inhibitor SB-203580 (A), protein kinase Cδ (PKCδ)
inhibitor rottlerin (B) and protein phosphatase 2B (PP2B) inhibitor on the activity levels of neutral sphingomyelinase 2 (nSMase2) and acid
sphingomyelinase (aSMase) were examined using a sphingomyelinase assay kit (C). (D) Protein expression and activity levels of nSMase2 in the
rat hippocampus were detected in the different groups. Data are presented as the means ± SEM of four separate experiments (n = 4). *P < 0.05
vs. sham control. #P < 0.05 vs. ischemia solvent control.
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clearly showed that ceramide content began to increase
when primary astrocytes were deprived of oxygen-glucose
in vitro for 3 h and then provided with both oxygen and
glucose for 30 min. The increment was considerable when
the length of deprivation reached 6 h (Figure 8A). In
addition, astrocytes were treated with DNR (0.5 μM)
for 24 h, which resulted in the generation of large
amounts of ceramide compared with the control
group and the solvent group (Figure 8B), indicating
that DNR could induce ceramide generation by activating
nSMase2. A cell coculture model, namely, neurons and
astrocyte cells (OGD for 6 h and both oxygen and glucose
for 30 min), was subsequently adopted to explore the
relationship between ceramide accumulation and neuronal
damage. This revealed that neuronal injury appeared with
decreased MAP2 tags after coculture (0.78-fold vs. control;
P < 0.05) (Figure 8C); DNR treatment in astrocytes
induced the apoptosis of neurons, which was established
using MAP2 labeling and a TUNEL assay (0.71-fold or
5.37-fold vs. vehicle, respectively; P < 0.05) (Figure 8D);
and PDTC significantly reversed this situation when used
in combination with DNR, established using a MAP2
labeling assay (1.87-fold vs. vehicle; P < 0.05) (Figure 8E).
Collectively, these results suggest that cerebral ischemia
can induce the activation of nSMase2 in astrocytes to
generate ceramide and then mediate the secondary
Figure 6 Effect of the A2B adenosine receptor/p38 mitogen-activated protein kinase pathway on the early initiation of ischemia-
induced neutral sphingomyelinase 2/ceramide. (A) Phosphorylation levels of p38 mitogen-activated protein kinase (p38MAPK) were detected
in the rat hippocampus after post-ischemia-reperfusion (post-I/R) of different durations (0.5 h, 1 h and 6 h). After A2B adenosine receptor inhibitor
MRS-1754 or its solvent was injected into the lateral ventricle, 30-min post-I/R followed. (B) Protein expression and activity levels of neutral
sphingomyelinase 2 (nSMase2) and (C) phosphorylation levels of p38MAPK in the rat hippocampus were detected in the different groups. (D)
Content of ceramide in the rat hippocampus was determined using immunohistochemistry in MRS-1754 and its solvent groups. Data representat
the means ± SEM of at least four separate experiments (n = 4). *P < 0.05 vs. sham control. #P < 0.05 vs. ischemia solvent control.
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damage of neurons through an inflammatory response
regulated by NF-κB.
Discussion
Over the past several decades, increasing attention
has been paid to the effects of neuronal activities in
stroke research [48,49]; however, these efforts have
failed to provide a stroke treatment [50,51]. To improve
the chances of finding an effective stroke treatment, a
broader focus on the loss and dysfunction of non-
neuronal cell types is required. Of the several glial
cell types, astrocytes are the most abundant cell type
and play key roles in the physiology and pathology of
the central nervous system [52,53]. In the present
study, ceramide, which is a risk factor for neuronal
damage, was found to be accumulated in the astro-
cytes, but not in the neurons, of the rat hippocampus
after ischemia.
Ceramide, which is a lipid second messenger, is known to
be involved in neuronal damage through intracellular sig-
naling pathways in response to harmful stimuli [9,10,44].
However, the role of ischemia-induced ceramide produc-
tion in astrocytes is poorly understood. In the present
study, the ceramide signal was found to be related to
a variety of proinflammatory cytokines, including TNF-α,
IL-1β and IL-6 production, as a result of NF-κB signaling.
First, ceramide accumulation induced by an nSMase2
agonist [45] could effectively stimulate the increment
of proinflammatory cytokine mRNA levels in the
hippocampi. Second, the reduction of ceramide levels
by an nSMase2 inhibitor could attenuate mRNA levels of
proinflammatory cytokines in the hippocampus following
ischemia, suggesting that ceramide signals are closely
associated with neuroinflammation in the rat hippocampi
in response to forebrain ischemia, which is similar to find-
ings in previous reports [44,54-57]. Third, the inactivation
Figure 7 Effect of the neutral sphingomyelinase 2/ceramide pathway on inflammation after cerebral ischemia. Real-time polymerase
chain reaction was performed to detect the mRNA levels of interleukin 1β (IL-1β), IL-6 and tumor necrosis factor α (TNF-α) after different
treatments. (A) Sham group with daunorubicin (DNR) stimuli of different durations (1 h, 6 h, 12 h, 24 h and 48 h). Injection with GW4869 (B) or
pyrrolidine dithiocarbamate (PDTC) (C) into the lateral ventricle prior to 30-min reperfusion postischemia. Data are presented as the means ± SEM
of at least four separate experiments (n = 4). *P < 0.05 vs. sham control. #P < 0.05 vs. ischemia solvent control.
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of NF-κB signaling could decrease the production of
proinflammatory cytokines (TNF-α, IL-1β and IL-6)
in response to ceramide signaling, suggesting that
the ceramide-induced upregulation of proinflammatory
cytokine is dependent on NF-κB signaling.
Inflammation induced by ceramide in astrocytes was
found to be closely associated with neuronal damage
following cerebral ischemia. The data from the Transwell
experiments suggest that ceramide accumulation in the
astrocytes can result in primary neuron damage in re-
sponse to OGD and activation of the nSMase2/ceramide
pathway, which could be reversed by inhibiting NF-κB
signaling. Inflammation-related cytokine release from
activated astrocytes is thought to be characteristic of some
neurodegenerative diseases, such as Alzheimer disease,
which is associated with progressive neuronal damage
[37,38,58-60]. Therefore, the present study hypothesized
that activated astrocytes might be involved in the damage
and loss of neurons in rat hippocampi as a result of
ceramide-induced neuroinflammation following transient
forebrain ischemia.
How is ceramide signaling controlled after cerebral
ischemia? The present study has highlighted the import-
ance of nSMase2 in the ceramide accumulation that oc-
curred in the rat hippocampus following cerebral ischemia,
which was activated especially within astrocytes [44,52,53].
nSMase activity was upregulated after cerebral ischemia, in
accordance with an early accumulation of ceramide. Mean-
while, the downregulation of nSMase2 by either a chemical
inhibitor or siRNA reduced ceramide production in hippo-
campal and primary astrocytes. However, the inhibition of
aSMase had no effect on the ischemia-induced activation of
astrocytes, emphasizing the possible specificity of the effect.
Previous studies have demonstrated the involvement of
nSMase2 in astrocyte ceramide accumulation in response
to the stimulation of fibrillar amyloid-β peptide [44]. The
Figure 8 Effect of in vitro oxygen-glucose deprivation in primary rat astrocytes on peripheral neuron injury. The double-staining of
ceramide and 4′,6-diamidino-2-phenylindole were detected by immunofluorescence in the different groups after primary rat astrocytes were deprived
of oxygen-glucose in vitro for 3 h and 6 h, before regaining 30 min oxygen-glucose (A), or were treated with daunorubicin (DNR) for 24 h (B). (C) After
primary rat astrocytes were deprived of oxygen-glucose in vitro for 6 h (before regaining 30-min oxygen-glucose), they were cocultured with primary
rat neurons for 12 h and the latter were labeled with microtubule-associated protein 2 (MAP2) fluorescence. (D) After pretreatment with DNR for 24 h,
astrocytes were cocultured with neurons for 12 h and then MAP2 and terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate
nick-end labeling staining were used to detect neuronal injury. (E) After concurrent pyrrolidine dithiocarbamate (PDTC) and DNR pretreatment,
astrocytes were cocultured with neurons for 12 h and the latter were labeled with MAP2 fluorescence (n = 4).
Gu et al. Journal of Neuroinflammation 2013, 10:109 Page 13 of 16
http://www.jneuroinflammation.com/content/10/1/109
present study also suggests that the inhibition of
nSMase2 could effectively attenuate the expression of
proinflammatory cytokines in ischemia-stimulated astro-
cytes (associated with ceramide signaling). Therefore, the
inhibition of nSMase2 in the astrocytes could also partly
reverse the neuronal damage that occurred in response to
cerebral ischemia. Furthermore, the cellular localization of
nSMase2 in astrocytes but not in neurons supports its
association with ceramide production. The data indicate
that nSMase2 plays a key role in ischemia-induced
ceramide accumulation and in its function within rat
hippocampal astrocytes.
nSMase2 can be activated by TNF-α stimuli through
the binding of nSMase2 to TNF-αR/RACK1/EED and is
important for inflammatory signaling [27-29]. In the
present study, coimmunoprecipitation data suggest that
cerebral ischemia induced the increased binding of
nSMase2 with RACK1 and EED, which might have been
associated with nSMase2 activation in the early phase of
ischemia. However, the inhibition of TNF-αR attenuated
the nSMase2 activity to some extent, suggesting that the
TNF-αR/RACK1/EED pathway plays a secondary role in
the upregulation of nSMase2 activity in hippocampal
astrocytes following ischemia. Meanwhile, TNF-α has
been reported to upregulate aSMase activity and subse-
quently modulate NF-κB-dependent inflammatory signaling
[61,62], but the ischemia-induced activation of SMase is
not linked to aSMase. The data in the current study suggest
that ischemia-induced nSMase2 activation might have
been partly dependent on the TNF-αR signaling pathway.
Further investigation is required to examine other possible
mechanisms underlying nSMase2 activation.
Phosphorylation plays a crucial role in nSMase2 activity
[32-34]. In the present study, p38, but not PKCζ or PP2B,
was found to be involved in nSMase2 activation in the rat
hippocampi following ischemia. First, cerebral ische-
mia induced the rapid upregulation of p38 activity, in
accordance with nSMase2 activation at 30 min post-I/R.
Second, the p38 inhibitor could reverse the upregulation
of nSMase2 and reduce ceramide levels in response to
ischemia. Previous studies have demonstrated that p38
can result in nSMase2 activation through the phosphoryl-
ation of its special site and that it is associated with
inflammation stress [35]. Furthermore, the A2BAR inhibitor
can also result in downregulation of nSMase2 activity and
ceramide levels, which are closely linked to p38 dephos-
phorylation. It has been reported that A2BAR plays a key
role in the rapid activation of p38 and the subsequent
Figure 9 Process flow diagram of signaling pathway. Specific accumulation of ceramide in astrocytes can be induced by cerebral ischemia-
reperfusion (I/R), of which activation of neutral sphingomyelinase 2 (nSMase2) by the A2B adenosine receptor (A2BAR)/p38 mitogen-activated
protein kinase (p38MAPK) pathway is the major mechanism for ceramide production. Meanwhile, the binding of the TNF-αR-RACK1-EED complex
via their WD repeat domains with nSMase2 can initiate its activity only in part. More importantly, the ischemia-induced accumulation of ceramide
in astrocytes can upregulate the generation of proinflammatory factors such as interleukin 1β (IL-1β), IL-6 and tumor necrosis factor α (TNF-α)
mediated by nuclear factor κB (NF-κB), leading to secondary damage of hippocampal neurons.
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upregulation of inflammation. Although there is contro-
versy regarding whether the effects of A2BAR are harmful
or beneficial, A2BAR is widely thought to be involved in the
inflammatory response [35,36]. p38, nSMase2 and ceramide
signaling are closely associated with the upregulation of
inflammatory factors. Therefore, this study supports the
viewpoint that A2BAR/p38 has a crucial role in the activa-
tion of the nSMase2/ceramide pathway and the underlying
inflammation in rat hippocampi in response to ischemia.
Conclusions
The results of this study reveal that cerebral ischemia
induced the activation of the nSMase2/ceramide pathway in
astrocytes, but not neurons in the rat hippocampus. This
involved the upregulation of preinflammation signaling and
neuronal damage resulting from a neuroinflammation
mediator. However, nSMase2 activation was associated
with the TNF-αR/RACK1 pathway, and ischemia-induced
A2BAR upregulation and p38 activation played a key role in
nSMase2/ceramide pathway signaling (Figure 9). These data
highlight the need to unravel the mechanisms of ceramide
signaling in activated astrocytes and astrocyte-mediated
neuronal damage resulting from neuroinflammation.
Such information would provide significant insight
into the pathophysiology of cerebral ischemia and aid
the development of treatment paradigms.
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